智通财经APP讯，森松国际(02155)公布，于2024年9月30日，森松制药(该公司的全资附属公司)的股东已批准森松制药采纳股权激励计划。根据股权激励计划，森松制药拟透过注资向激励对象授出合共人民币1286.871万元拟新增注册资本，占紧随注资完成后其注册资本总额的约14.91%。于注资完成后，激励对象将直接持有森松制药的股权。
于本公告日期，该公司以直接和间接方式拥有森松制药100%股权。假设激励对象根据股权激励计划完成注资;及自本公告日期至注资完成，森松制药的注册资本总额及公司于森松制药的股权并无其他变动，该公司于森松制药的股权将于注资完成后由100%减少至约85.09%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.